X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (65241) 65241
Newsletter (7389) 7389
Newspaper Article (712) 712
Book Chapter (160) 160
Magazine Article (106) 106
Transcript (69) 69
Dissertation (46) 46
Conference Proceeding (39) 39
Publication (29) 29
Trade Publication Article (25) 25
Book / eBook (17) 17
Web Resource (11) 11
Streaming Video (3) 3
Book Review (1) 1
Journal / eJournal (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52272) 52272
science & technology (44605) 44605
life sciences & biomedicine (42713) 42713
oncology (29484) 29484
male (28816) 28816
female (28783) 28783
lung cancer, non-small cell (26741) 26741
lung neoplasms - pathology (24729) 24729
middle aged (24514) 24514
aged (23511) 23511
carcinoma, non-small-cell lung - pathology (22798) 22798
lung cancer (20338) 20338
carcinoma, non-small-cell lung - drug therapy (19170) 19170
lung neoplasms - drug therapy (18533) 18533
cancer (17737) 17737
adult (14774) 14774
carcinoma, non-small-cell lung - genetics (12184) 12184
prognosis (11997) 11997
research (11968) 11968
lung neoplasms - genetics (11905) 11905
neoplasm staging (11349) 11349
non-small cell lung cancer (11181) 11181
care and treatment (11109) 11109
aged, 80 and over (9764) 9764
lung neoplasms - mortality (9692) 9692
carcinoma, non-small-cell lung - mortality (9604) 9604
chemotherapy (9229) 9229
respiratory system (8934) 8934
treatment outcome (8262) 8262
lung neoplasms - metabolism (8156) 8156
carcinoma, non-small-cell lung - metabolism (8094) 8094
non-small cell lung carcinoma (8059) 8059
carcinoma, non-small-cell lung - surgery (7386) 7386
lung neoplasms - surgery (7360) 7360
oncology, experimental (6950) 6950
antineoplastic combined chemotherapy protocols - therapeutic use (6866) 6866
metastasis (6665) 6665
cell line, tumor (6512) 6512
retrospective studies (6396) 6396
tumors (6377) 6377
analysis (6346) 6346
mutation (6310) 6310
survival rate (5656) 5656
surgery (5625) 5625
lung cancer, small cell (5430) 5430
animals (5337) 5337
antineoplastic agents - therapeutic use (5287) 5287
genetic aspects (5257) 5257
survival analysis (5244) 5244
carcinoma, non-small-cell lung - radiotherapy (5072) 5072
carcinoma, non-small-cell lung - therapy (5025) 5025
lung neoplasms - therapy (4984) 4984
lung neoplasms - radiotherapy (4873) 4873
apoptosis (4645) 4645
patients (4564) 4564
cancer therapies (4550) 4550
abridged index medicus (4446) 4446
health aspects (4271) 4271
nsclc (4176) 4176
carcinoma, non-small-cell lung - diagnosis (4138) 4138
lung neoplasms - diagnosis (4133) 4133
hematology, oncology and palliative medicine (4025) 4025
immunohistochemistry (3982) 3982
gene expression (3824) 3824
respiratory tract diseases (3789) 3789
radiotherapy (3672) 3672
mice (3563) 3563
follow-up studies (3538) 3538
disease-free survival (3500) 3500
non-small-cell lung cancer (3471) 3471
development and progression (3421) 3421
medical prognosis (3369) 3369
carcinoma, non-small-cell lung - secondary (3334) 3334
combined modality therapy (3228) 3228
carcinoma, non-small-cell lung - diagnostic imaging (3227) 3227
lung neoplasms - diagnostic imaging (3196) 3196
proteins (3175) 3175
gene expression regulation, neoplastic (3139) 3139
epidermal growth factor (3104) 3104
cell biology (3086) 3086
risk factors (3052) 3052
kinases (2973) 2973
radiology, nuclear medicine & medical imaging (2953) 2953
medicine & public health (2936) 2936
receptor, epidermal growth factor - genetics (2935) 2935
pharmacology & pharmacy (2931) 2931
adenocarcinoma - pathology (2925) 2925
medical research (2866) 2866
cisplatin - administration & dosage (2847) 2847
antineoplastic agents - pharmacology (2657) 2657
studies (2634) 2634
clinical trials (2620) 2620
survival (2581) 2581
protein kinase inhibitors - therapeutic use (2519) 2519
pathology (2503) 2503
biochemistry & molecular biology (2498) 2498
lung neoplasms (2471) 2471
kaplan-meier estimate (2416) 2416
lymphatic metastasis (2412) 2412
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (70339) 70339
Chinese (1762) 1762
Japanese (1010) 1010
French (900) 900
German (605) 605
Spanish (254) 254
Russian (164) 164
Polish (159) 159
Italian (154) 154
Portuguese (127) 127
Korean (92) 92
Czech (54) 54
Turkish (53) 53
Dutch (42) 42
Hungarian (41) 41
Danish (18) 18
Bulgarian (17) 17
Serbian (17) 17
Norwegian (16) 16
Romanian (16) 16
Croatian (12) 12
Finnish (8) 8
Hebrew (8) 8
Slovak (7) 7
Icelandic (6) 6
Lithuanian (6) 6
Swedish (5) 5
Bosnian (3) 3
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, pp. e0136023 - e0136023
Background Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Carcinoma, Squamous Cell - mortality | Neoplasm Grading | Biomarkers, Tumor - metabolism | Female | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Carcinoma, Squamous Cell - therapy | Programmed Cell Death 1 Receptor - metabolism | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | B7-H1 Antigen - metabolism | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Care and treatment | Physiological aspects | Genetic aspects | Research | Lung cancer, Non-small cell | Apoptosis | Immunohistochemistry | Thoracic surgery | PD-1 protein | Lung cancer | Clinical trials | Oncology | Cancer therapies | Lymph nodes | Subgroups | Proteins | Rank tests | Regression models | Bcl-x protein | Lymphocytes | Immunotherapy | Medical research | Immunoglobulins | Squamous cell carcinoma | Cell survival | Cytokines | Hematology | Tumor cells | Non-small cell lung carcinoma | Breast cancer | Regression analysis | Patients | Medicine | Pathology | Chemotherapy | Hospitals | Cell death | Medical prognosis | PD-L1 protein | Ligands | Diagnostic systems | Solid tumors | Cancer | Tumors | Index Medicus
Journal Article
PloS one, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, pp. e57020 - e57020
.... Therapy resistance of a tumor is thought to be related to cancer stem cells (CSCs) within the tumors. There have been indications that the lung cancer is propagated and maintained by a small population of CSCs... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Cadherins - metabolism | Vimentin - metabolism | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Homeodomain Proteins - metabolism | Humans | Lung Neoplasms - metabolism | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Antigens, CD - genetics | Antigens, CD - metabolism | Octamer Transcription Factor-3 - genetics | Small Cell Lung Carcinoma - metabolism | Adenocarcinoma - metabolism | Neoplastic Stem Cells - metabolism | Vimentin - genetics | Thy-1 Antigens - genetics | Hyaluronan Receptors - metabolism | Biomarkers, Tumor - metabolism | Neoplastic Stem Cells - pathology | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Cadherins - genetics | Lung Neoplasms - genetics | Carcinoma, Large Cell - metabolism | Nanog Homeobox Protein | Immunophenotyping | Small Cell Lung Carcinoma - genetics | Mice, SCID | Hyaluronan Receptors - genetics | Homeodomain Proteins - genetics | Thy-1 Antigens - metabolism | Small Cell Lung Carcinoma - pathology | Animals | Octamer Transcription Factor-3 - metabolism | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Primary Cell Culture | Care and treatment | Analysis | Stem cells | Cancer cells | Physiological aspects | Research | Cancer | Adenocarcinoma | Vimentin | Cell culture | Therapy | Biotechnology | Thoracic surgery | Mesenchyme | Oct-4 protein | Lung cancer | Radiation | Population studies | Identification | Biology | mRNA | Metastasis | Cancer therapies | CD90 antigen | N-Cadherin | Immunology | CD44 antigen | Population | Medical research | Squamous cell carcinoma | Hematology | Small cell lung carcinoma | Cell division | Tumor cell lines | Gene expression | Cadherin | Spheroids | Morbidity | Medicine | Pathology | Lungs | Medical prognosis | Pancreatic cancer | Irradiation | Prostate | Tumors | Index Medicus
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 07/2017, Volume 77, Issue 13, pp. 3540 - 3550
.... In this study, we evaluated tumor specimens from 65 patients with melanoma, lung nonsquamous, squamous cell lung or head and neck cancers who were treated with the approved PD1-targeting antibodies... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Gene Expression - drug effects | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Squamous Cell Carcinoma of Head and Neck | Melanoma - genetics | Gene Expression - immunology | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Head and Neck Neoplasms - drug therapy | Gene Expression Profiling - methods | Melanoma - pathology | Head and Neck Neoplasms - pathology | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Melanoma - immunology | Melanoma - drug therapy | Nivolumab | Head and Neck Neoplasms - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | PD-1 protein | CD8 antigen | Antibodies | Lymphocytes T | Killer cells | Cell activation | Lymphocytes | Natural killer cells | Signatures | Immune system | Squamous cell carcinoma | Head | Immune response | Small cell lung carcinoma | Tumor-infiltrating lymphocytes | Melanoma | Lung carcinoma | Gene expression | Ribonucleic acid--RNA | Patients | CD4 antigen | Immune checkpoint | Reproducibility | PD-L1 protein | Biomarkers | Head and neck cancer | Interferon | Solid tumors | Cancer | Tumors | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 11/2014, Volume 90, Issue 4, pp. 834 - 842
...) in stage III non-small cell lung cancer (NSCLC). Methods and Materials We retrospectively reviewed 91 cases with stage III NSCLC treated with definitive chemoradiation therapy... 
Radiology | Hematology, Oncology and Palliative Medicine | Oncology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Risk Assessment - methods | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Lung Neoplasms - radiotherapy | Tomography, X-Ray Computed - methods | Lung Neoplasms - pathology | Male | Carcinoma, Squamous Cell - diagnostic imaging | Carcinoma, Squamous Cell - radiotherapy | Chemoradiotherapy | Carcinoma, Squamous Cell - mortality | Karnofsky Performance Status | Female | Radiotherapy Planning, Computer-Assisted | Adenocarcinoma - radiotherapy | Carcinoma, Non-Small-Cell Lung - pathology | Reproducibility of Results | Movement | Induction Chemotherapy - methods | Proportional Hazards Models | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Contrast Media | Lung Neoplasms - diagnostic imaging | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Adenocarcinoma - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Exhalation | Neoplasm Staging | Adenocarcinoma - mortality | Sects | Lung cancer, Small cell | Physicists | Lung cancer, Non-small cell | Index Medicus | REVIEWS | PATIENTS | IMAGE PROCESSING | NEOPLASMS | LUNGS | METASTASES | RADIOLOGY AND NUCLEAR MEDICINE | CLASSIFICATION | COMPARATIVE EVALUATIONS | CAT SCANNING | HAZARDS
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 08/2014, Volume 89, Issue 5, pp. 1084 - 1091
.... We sought to investigate the mechanisms underlying radiation-induced lymphopenia and its associations with patient outcomes in non-small cell lung cancer (NSCLC... 
Radiology | Hematology, Oncology and Palliative Medicine | Oncology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Male | Carcinoma, Squamous Cell - radiotherapy | Lymphopenia - etiology | Lymphopenia - mortality | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Lung - radiation effects | Adenocarcinoma - radiotherapy | Lymphopenia - diagnosis | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Lung - pathology | Treatment Outcome | Tumor Burden | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Regression Analysis | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Care and treatment | Patient outcomes | Immunotherapy | Lung cancer, Small cell | Lung cancer, Non-small cell | Lymphocytopenia | Tumors | Chemotherapy | Lymphocytes | Analysis | Radiation | Cancer | Index Medicus | PATIENTS | LYMPHOPENIA | NEOPLASMS | LUNGS | MONOCYTES | NEUTROPHILS | CORRELATIONS | RADIATION DOSES | CHEMOTHERAPY | MULTIVARIATE ANALYSIS | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | LYMPHOCYTES
Journal Article